Sp1108
REFERRING THE PATIENT WITH ALCOHOLIC HEPATITIS: WHO MAY BE A CANDIDATE?
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
When and who to refer patients in possible need of liver transplant is frought with challenges. The most important management decision to make for many of these patients is when to refer. We aim to outline and guide these decisions in the most challenging situations. Experience in transplanting for acute alcohol related hepatitis and ACLF continue to evolve and the speakers will update on this evolution. What if your patient is sick but has low MELD? Learn about the transplant options for these individuals.
When and who to refer patients in possible need of liver transplant is frought with challenges. The most important management decision to make for many of these patients is when to refer. We aim to outline and guide these decisions in the most challenging situations. Experience in transplanting for acute alcohol related hepatitis and ACLF continue to evolve and the speakers will update on this evolution. What if your patient is sick but has low MELD? Learn about the transplant options for these individuals.
Presenter
Virginia Commonwealth University
Tracks
Related Products
INTRODUCTION
SOCIETY: AGA
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
